vs
Apellis Pharmaceuticals, Inc.（APLS）与Eastern Bankshares, Inc.（EBC）财务数据对比。点击上方公司名可切换其他公司
Eastern Bankshares, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$295.9M vs $199.9M），Eastern Bankshares, Inc.净利率更高（22.1% vs -29.5%，领先51.6%），Eastern Bankshares, Inc.同比增速更快（710.6% vs -5.9%），过去两年Eastern Bankshares, Inc.的营收复合增速更高（38.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
东方银行股份有限公司总部位于美国马萨诸塞州波士顿，2020年完成股份化改制前，是美国历史最悠久、规模最大的互助银行，同时也是马萨诸塞州规模最大的社区银行，深耕本地金融服务，在区域零售及小微金融领域拥有深厚的运营积淀。
APLS vs EBC — 直观对比
营收规模更大
EBC
是对方的1.5倍
$199.9M
营收增速更快
EBC
高出716.5%
-5.9%
净利率更高
EBC
高出51.6%
-29.5%
两年增速更快
EBC
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $295.9M |
| 净利润 | $-59.0M | $65.3M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 22.1% |
| 营收同比 | -5.9% | 710.6% |
| 净利润同比 | -62.2% | -34.4% |
| 每股收益（稀释后） | $-0.40 | $0.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSEBC
| Q1 26 | — | $295.9M | ||
| Q4 25 | $199.9M | $37.5M | ||
| Q3 25 | $458.6M | $241.5M | ||
| Q2 25 | $178.5M | $244.9M | ||
| Q1 25 | $166.8M | $31.1M | ||
| Q4 24 | $212.5M | $216.5M | ||
| Q3 24 | $196.8M | $203.4M | ||
| Q2 24 | $199.7M | $154.0M |
净利润APLSEBC
| Q1 26 | — | $65.3M | ||
| Q4 25 | $-59.0M | $99.5M | ||
| Q3 25 | $215.7M | $106.1M | ||
| Q2 25 | $-42.2M | $100.2M | ||
| Q1 25 | $-92.2M | $-217.7M | ||
| Q4 24 | $-36.4M | $60.8M | ||
| Q3 24 | $-57.4M | $-6.2M | ||
| Q2 24 | $-37.7M | $26.3M |
营业利润率APLSEBC
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 38.9% | ||
| Q2 25 | -18.6% | 41.0% | ||
| Q1 25 | -50.0% | -590.9% | ||
| Q4 24 | -12.3% | 33.3% | ||
| Q3 24 | -24.0% | -1.6% | ||
| Q2 24 | -14.7% | 24.7% |
净利率APLSEBC
| Q1 26 | — | 22.1% | ||
| Q4 25 | -29.5% | 265.6% | ||
| Q3 25 | 47.0% | 44.0% | ||
| Q2 25 | -23.6% | 40.9% | ||
| Q1 25 | -55.3% | -699.2% | ||
| Q4 24 | -17.1% | 28.1% | ||
| Q3 24 | -29.2% | -3.0% | ||
| Q2 24 | -18.9% | 17.1% |
每股收益（稀释后）APLSEBC
| Q1 26 | — | $0.29 | ||
| Q4 25 | $-0.40 | $0.48 | ||
| Q3 25 | $1.67 | $0.53 | ||
| Q2 25 | $-0.33 | $0.50 | ||
| Q1 25 | $-0.74 | $-1.08 | ||
| Q4 24 | $-0.30 | $0.29 | ||
| Q3 24 | $-0.46 | $-0.03 | ||
| Q2 24 | $-0.30 | $0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $551.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $4.3B |
| 总资产 | $1.1B | $30.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSEBC
| Q1 26 | — | $551.7M | ||
| Q4 25 | $466.2M | $507.6M | ||
| Q3 25 | $479.2M | $703.4M | ||
| Q2 25 | $370.0M | $948.3M | ||
| Q1 25 | $358.4M | $609.0M | ||
| Q4 24 | $411.3M | $1.9B | ||
| Q3 24 | $396.9M | $1.7B | ||
| Q2 24 | $360.1M | $1.4B |
股东权益APLSEBC
| Q1 26 | — | $4.3B | ||
| Q4 25 | $370.1M | $4.3B | ||
| Q3 25 | $401.2M | $3.8B | ||
| Q2 25 | $156.3M | $3.7B | ||
| Q1 25 | $164.2M | $3.6B | ||
| Q4 24 | $228.5M | $3.6B | ||
| Q3 24 | $237.1M | $3.7B | ||
| Q2 24 | $264.3M | $3.0B |
总资产APLSEBC
| Q1 26 | — | $30.6B | ||
| Q4 25 | $1.1B | $30.6B | ||
| Q3 25 | $1.1B | $25.5B | ||
| Q2 25 | $821.4M | $25.5B | ||
| Q1 25 | $807.3M | $25.0B | ||
| Q4 24 | $885.1M | $25.6B | ||
| Q3 24 | $901.9M | $25.5B | ||
| Q2 24 | $904.5M | $21.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSEBC
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $432.4M | ||
| Q3 25 | $108.5M | $157.1M | ||
| Q2 25 | $4.4M | $123.9M | ||
| Q1 25 | $-53.4M | $47.3M | ||
| Q4 24 | $19.4M | $283.8M | ||
| Q3 24 | $34.1M | $108.3M | ||
| Q2 24 | $-8.3M | $54.3M |
自由现金流APLSEBC
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $-53.4M | — | ||
| Q4 24 | $19.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-8.4M | — |
自由现金流率APLSEBC
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | -32.0% | — | ||
| Q4 24 | 9.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.2% | — |
资本支出强度APLSEBC
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — |
现金转化率APLSEBC
| Q1 26 | — | — | ||
| Q4 25 | — | 4.35× | ||
| Q3 25 | 0.50× | 1.48× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.67× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.06× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EBC
暂无分部数据
